dacarbazine has been researched along with withaferin a in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cohen, MS; Grogan, PT; Sarkaria, JN; Timmermann, BN | 1 |
1 other study(ies) available for dacarbazine and withaferin a
Article | Year |
---|---|
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Heme Oxygenase-1; Humans; MAP Kinase Signaling System; O(6)-Methylguanine-DNA Methyltransferase; Oxidative Stress; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Withanolides | 2014 |